At least two clinical trials of remdesivir for 2019-nCoV are under way in China,
there need to be large, double blind, placebo controlled studies. These are very difficult to perform in very sick patients for ethical reasons.
Ethics isn't much of a problem inside China..
but Gilead's remdesevir patent is